Ajay NarasimhaSenior Vice President, Corporate Strategy & Business Development at Mirum PharmaceuticalsSpeaker
Profile
Ajay Narasimha is Senior Vice President of Corporate Strategy and Business Development at Mirum Pharmaceuticals, where he oversees the company's corporate development and portfolio strategy efforts. He has led key transactions at Mirum, including the 2025 acquisition of Bluejay Therapeutics and the 2026 licensing agreement with Incyte for zilurgisertib, a therapy for fibrodysplasia ossificans progressiva, a rare genetic disease. Prior to joining Mirum, he spent nearly 12 years at Genentech, where he led business development for immunology, infectious disease, and cardiometabolism. His experience spans large pharma and rare disease biotech, with expertise in evaluating assets, structuring partnerships, and identifying opportunities for long-term growth.
Agenda Sessions
Strategic Exit Planning for Rare Disease Companies – M&A, Partnerships and Alternative Pathways
, 11:45amView Session
